Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Wilms Tumor 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Histiocytosis, Langerhans-Cell 1Hepatoblastoma 1Glioma 1Ependymoma 1

Interventions

X-Rays 6Phantoms, Imaging 6Magnetic Resonance Spectroscopy 6Flow Cytometry 6Specimen Handling 5Nuclear Medicine Department, Hospital 5Biopsy 5Therapeutics 4Methylprednisolone 4Cyclophosphamide 4Radiotherapy 3Psychiatric Rehabilitation 3Polymerase Chain Reaction 3Immunologic Techniques 3Antilymphocyte Serum 3Amplified Fragment Length Polymorphism Analysis 3ulixertinib 2trametinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2olaparib 2liposomal amphotericin B 2larotrectinib 2ivosidenib 2erdafitinib 2ensartinib 2dabrafenib 2Voriconazole 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroblastoma × Pharmacogenomic Variants × Myeloid × Clear all
NCT03698994 2026-05-27

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
20 enrolled 9 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡